Cambrex Expands Generic API Research and Development Capabilities at Milan, Italy Site
June 12 2018 - 8:00AM
Cambrex Corporation (NYSE:CBM), the leading manufacturer of small
molecule innovator and generic Active Pharmaceutical Ingredients
(APIs), today announced that it will expand research and
development capabilities at its site in Paullo, Milan, Italy. The
investment will be in the construction of a new 150m² R&D
laboratory and the recruitment of additional scientists to increase
the number of generic APIs in the company’s development portfolio.
The new laboratory will include 14 fume hoods
and will combine both chemistry and analytical development
capabilities, with the installation of glass lined reactors, as
well as analytical instruments including multiple high and
ultra-performance liquid chromatography, and gas chromatography
systems. It is estimated building work will be completed by the end
of 2018, allowing installation and validation of the analytical
instruments to take place in Q1 2019.
“The generic API industry is growing due to the
continued expiry of product patents, which results in the constant
flow of new generic entrants to the market,” commented Aldo
Magnini, Managing Director, Cambrex Milan. “The new laboratory will
increase the number of programs we can be active in at any one
time, allowing us to expand our portfolio of generic products.”
Cambrex currently manufactures over 70 generic
APIs which are produced to cGMP standards and the Milan site
comprises seven production departments, supported by a pilot plant,
kilo-scale plant and development and analytical laboratories.
About CambrexCambrex
Corporation is an innovative life sciences company that provides
products, services and technologies to accelerate the development
and commercialization of small molecule therapeutics. The Company
offers Active Pharmaceutical Ingredients (APIs), advanced
intermediates and enhanced drug delivery products for branded and
generic pharmaceuticals. Development and manufacturing capabilities
include enzymatic biotransformations, high potency APIs, high
energy chemical synthesis, controlled substances and continuous
processing. For more information, please visit www.cambrex.com.
Contact: |
Alex Maw |
|
Director, Marketing and
Communications |
|
Tel: +44 7803 443
155 |
|
Email:
alex.maw@cambrex.com |
Cambrex (NYSE:CBM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cambrex (NYSE:CBM)
Historical Stock Chart
From Apr 2023 to Apr 2024